// App-Quantinova.ai

: Effectiveness and Safety of Direct Switch to Indacaterol/Glycopyrronium from Previous Treatments in Patients with Moderate-to-Severe COPD: The POWER Study

Researchers

Presenter

  • A. McIvor

Principal Investigators

  • K. R. Chapman

  • S. M. Anees

  • I. Mayers

  • D. Rochdi

  • M. Djandji

  • D. Prefontaine

  • A. Kaplan

Medical Centers

  • Department of Medicine, McMaster University, Firestone Institute for Respiratory Health, Hamilton, ON, Canada,

  • Asthma and Airway Centre, University Health Network, University of Toronto, Toronto, ON, Canada,

  • Schulich School of Medicine & Dentistry- Windsor Campus, Windsor, ON, Canada,

  • Division of Preventive Medicine, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada

  • Novartis Pharma Canada Inc., Dorval, QC, Canada,

  • Family Physician Airways Group of Canada, University of Toronto, Toronto, ON, Canada.

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

Disease

  • N/A

Biomarkers

  • Catalase

Drug/Treatment

  • Seebri Breezhaler

  • indacaterol

  • Tiotropium bromide

Outcome

  • N/A

Study Design

  • Open Label

  • Multicenteric

  • Prospective

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved